Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes
Abstract Background In vivo genome editing offers a long-term therapeutic approach for monogenic diseases by directly modifying genetic sequences. However, its application to non-monogenic, noncommunicable diseases, which are the leading causes of global mortality, remains limited due to the lack of...
Saved in:
| Main Authors: | Jun Hirose, Emi Aizawa, Shogo Yamamoto, Shigenori Iwai, Keiichiro Suzuki |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-025-00959-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipid Nanoparticles Enable Efficient In Vivo DNA Knock-In via HITI-Mediated Genome Editing
by: Jun Hirose, et al.
Published: (2024-12-01) -
REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION
by: Zainab M. Al-Shammaa, et al.
Published: (2025-07-01) -
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01) -
Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01) -
GLP-1 Agonists, Willpower, and Weight Stigma: A Paradigm Shift for Obesity
by: Pablo Arrona-Cardoza
Published: (2025-08-01)